Search research articles
Contact Us
Filters
Showing results (31-40 of 41) with videos related to
Page
of 5
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
January 3, 2012
Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study
E Calvo, B Escudier, R J Motzer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 29, 2015
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis
S Bracarda, R Iacovelli, L Boni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 14, 2013
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)
L Fornaro, S Lonardi, G Masi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 28, 2013
A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN
B Melichar, S Bracarda, V Matveev, et al.
ESMO Real World Data and Digital Oncology
|
February 6, 2026
READY: REAl-world Data from an Italian compassionate use program of avelumab first-line maintenance for locallY advanced or metastatic urothelial carcinoma
L Antonuzzo, M Maruzzo, U De Giorgi, et al.
ESMO Open
|
July 19, 2023
An Italian multicenter retrospective real-life analysis of patients with brain metastases from renal cell carcinoma: the BMRCC study
V Internò, F Massari, R Rudà, et al.
British Journal of Cancer
|
June 19, 2015
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma
M E Gore, C Szczylik, C Porta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 17, 2024
Subcutaneous versus intravenous nivolumab for renal cell carcinoma
L Albiges, M T Bourlon, M Chacón, et al.
ESMO Open
|
December 9, 2022
Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program
S E Rebuzzi, A Signori, S Buti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2015
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†
A Kramar, S Negrier, R Sylvester, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 41) with videos related to
Sort By:
Page
of 5
European Journal of Cancer (Oxford, England : 1990)
|
January 3, 2012
Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study
E Calvo, B Escudier, R J Motzer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 29, 2015
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis
S Bracarda, R Iacovelli, L Boni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 14, 2013
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)
L Fornaro, S Lonardi, G Masi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 28, 2013
A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN
B Melichar, S Bracarda, V Matveev, et al.
ESMO Real World Data and Digital Oncology
|
February 6, 2026
READY: REAl-world Data from an Italian compassionate use program of avelumab first-line maintenance for locallY advanced or metastatic urothelial carcinoma
L Antonuzzo, M Maruzzo, U De Giorgi, et al.
ESMO Open
|
July 19, 2023
An Italian multicenter retrospective real-life analysis of patients with brain metastases from renal cell carcinoma: the BMRCC study
V Internò, F Massari, R Rudà, et al.
British Journal of Cancer
|
June 19, 2015
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma
M E Gore, C Szczylik, C Porta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 17, 2024
Subcutaneous versus intravenous nivolumab for renal cell carcinoma
L Albiges, M T Bourlon, M Chacón, et al.
ESMO Open
|
December 9, 2022
Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program
S E Rebuzzi, A Signori, S Buti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2015
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†
A Kramar, S Negrier, R Sylvester, et al.
Page
of 5